Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Certolizumab Pegol in Healthy Chinese Subjects
NCT02365948Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (4 arms), sponsored by UCB. Primary endpoints: Area under the plasma concentration-time curve from time zero up to the last analytically quantifiable concentration and Maximum plasma concentration. Started Mar 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02365948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365948.